

## Terumo Revises its Full-Year Financial Guidance for FY2021

TOKYO, JAPAN – February 9, 2022 – Terumo Corporation (TSE: 4543) today announced that it revised the full-year financial guidance for the year ending March 2022 (FY2021) from its last announcement on August 4, 2021.

### 1. Full-year financial guidance for FY2021 (From April 1, 2021 to March 31, 2022)

|                                      | Revenue<br>(Million yen) | Adjusted<br>operating<br>profit<br>(Million yen) | Operating<br>profit<br>(Million yen) | Profit<br>for the year<br>attributable to<br>the owners of<br>the parent<br>(Million yen) | Earnings per<br>share<br>(Yen) |
|--------------------------------------|--------------------------|--|--------------------------------------|---|--------------------------------|
| Prior guidance                       | 685,000                  | 137,000  | 120,000                              | 92,000  | 121.69                         |
| Revised<br>guidance                  | 697,000                  | 137,000  | 120,000                              | 92,000  | 121.66                         |
| Change in<br>amount                  | 12,000                   | 0  | 0                                    | 0   |                                |
| Rate of<br>change                    | 1.8%                     | 0.0%   | 0.0%                                 | 0.0%  |                                |
| (Reference)<br>Results for<br>FY2020 | 613,842                  | 115,927  | 98,386                               | 77,268  | 102.33                         |

### 2. Reasons for the revision

For the third quarter of FY2021, there was a recovery in demand for the Cardiac and Vascular Company, and sales was steady for the General Hospital Company and the Blood and Cell Technologies Company. This contributed to reaching the highest-ever quarter record for revenue. The guidance revision takes into account of this upside performance of FY2021 (YTD) as well as the result of reevaluating the assumed foreign exchange rate.

However, the adjusted operating profit, operating profit, and profit for the year attributable to the owners of the parent is deferred. This is due to the fact that for the fourth quarter the company expects an increase in cost, by factors such as decrease in demand coming from drop in medical procedures, inflation and decrease in capacity utilization. The company will strive to achieve the original guidance by adequately controlling other costs.

**About Terumo**

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

**Disclaimer**

Among the information that Terumo discloses, the forward-looking statements including financial projections contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.